These include a relative or absolute increase in glucagon secretion from alpha cells of the pancreas, elevated serum free fatty-acid concentrations, an impaired incretin effect (e.g., decreased secretion of glucagon-like peptide-1 [GLP-1]), enhanced renal reabsorption of glucose, and dysregulation of appetite control via decreased neurotransmitter response in the brain
Importantly, since the program operates independently of the employer's medical plan, GLP-1 utilization does not affect medical claims or future renewals
Cureus 15 , e46490 (2023)
#BloodFlowRestriction #BFR #Rehab #Recovery #Longevity To view or add a comment, sign in The gut microbiome looks measurably different in five common chronic conditions
Support: Many of the services on our list offer additional resources and support beyond medications to help you reach your goals and manage your weight long term
Orforglipron (Foundayo): Early data suggests plateaus at 6 to 10 months, with 14 to 17 percent weight loss in maintenance trials